Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation reports recurring developments across its global medical technology business, including financial results, investor conference participation, product studies and U.S. regulatory actions. The company’s solutions include hospital technologies, end-to-end plasma collection technologies for plasma centers and products used by blood centers to collect blood components.
Company news frequently centers on the VASCADE MVP and VASCADE MVP XL venous vascular closure systems, the NexSys PCS Plasma Collection System and Persona technology. Updates also cover FDA approvals or 510(k) clearances, clinical evidence supporting device use, earnings releases and presentations, and communications tied to the company’s plasma, blood center and hospital markets.
Haemonetics (NYSE: HAE) posted its third quarter fiscal 2026 results for the period ended December 27, 2025, on its Investor Relations website.
The company will host a conference call and live webcast at 8:00 a.m. ET on February 5, 2026, with a replay available from 11:00 a.m. ET on February 5, 2026 for one year. Earnings release and a supplemental presentation are posted and will be referenced on the call.
Vivasure Medical was acquired by Haemonetics (NYSE: HAE) in a transaction valued up to €185M (~$215M) payable on completion of certain milestones. Vivasure, based in Galway, develops fully absorbable polymer implants and delivery systems for minimally invasive arterial and venous vessel closure. Vivasure previously received an expanded CE mark for PerQseal Elite covering large-bore venous closure and has submitted a PMA application to the FDA for PerQseal Elite for arterial procedures. Haemonetics made a strategic investment in Vivasure in 2022 that included an acquisition option. PerQseal products are not currently available for sale in the United States.
Haemonetics (NYSE: HAE) acquired Vivasure Medical Limited, a Galway-based developer of the PerQseal Elite percutaneous large-bore vessel closure system.
The deal includes an upfront cash payment of €100 million (approximately €52 million net of prior investments/loans and adjustments) and up to €85 million of contingent consideration tied to sales growth and milestones. Haemonetics financed the acquisition with available cash on hand.
Vivasure submitted a PMA application to the U.S. FDA in 2025 and holds CE Mark approval in Europe for arterial and venous indications. The ELITE study reported 0% major complications at 30 days and immediate median time to hemostasis.
Haemonetics (NYSE: HAE) will release third quarter fiscal 2026 results at 6:00 am ET on Thursday, February 5, 2026. The company will host a conference call with investors and analysts at 8:00 am ET on February 5, 2026, accessible by teleconference after registration, which provides a dial-in number and personalized PIN. A live webcast will be available on Haemonetics' investor relations website at the provided link. A replay of the conference call and webcast will be available for one year starting February 5, 2026 at 11:00 am ET. Participants are recommended to join the call 10 minutes early.
Haemonetics (NYSE: HAE) announced that President and CEO Chris Simon will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 AM PT.
The presentation will be available live via audio webcast at the provided JPMorgan link and under the Events & Presentations section of Haemonetics' Investor Relations website. A replay will be posted approximately one hour after the live event and will remain available for 30 days.
Haemonetics (NYSE: HAE) announced its second quarter fiscal 2026 financial results for the period ended September 27, 2025 are available on the company's Investor Relations website.
The company will host a live conference call and webcast with investors and analysts at 8:00 a.m. ET on November 6, 2025. A replay will be available beginning at 11:00 a.m. ET on November 6, 2025 and will remain accessible for one year via the webcast link. Earnings materials posted include the Second Quarter Fiscal 2026 Earnings Release and a Supplemental Earnings Presentation.
Haemonetics (NYSE: HAE) will publish Q2 fiscal 2026 results at 6:00 AM ET on Thursday, November 6, 2025. The company will host a conference call with investors and analysts at 8:00 AM ET on November 6, 2025 to discuss results and answer questions.
Participants must register for teleconference access and will receive a dial-in number and personalized PIN; joining 10 minutes early is recommended. A live webcast will be available on Haemonetics' investor relations website at the provided webcast link. A replay of the call and webcast will be available for one year beginning November 6, 2025 at 11:00 AM ET.
Haemonetics Corporation (NYSE: HAE) has announced the availability of its first quarter fiscal year 2026 financial results on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on August 7, 2025, at 8:00 a.m. ET to discuss the results.
The conference call requires pre-registration, and participants are recommended to join 10 minutes before the event. A replay of the conference call and webcast will be accessible for one year starting from August 7, 2025, at 11:00 a.m. ET.
Haemonetics (NYSE: HAE) has scheduled the release of its first quarter fiscal year 2026 financial results for August 7, 2025 at 6:00 am ET. The company will host a conference call with investors and analysts at 8:00 am ET on the same day to discuss the results and take questions.
Participants can access the call via teleconference after completing registration, and are encouraged to join 10 minutes before the start. A live webcast will be available on Haemonetics' investor relations website, with a replay accessible for one year starting August 7, 2025, at 11:00 am ET.
Vivasure Medical has announced two significant regulatory milestones for its PerQseal® Elite vascular closure system. The company has submitted a Premarket Approval (PMA) application to the FDA for arterial procedures and received European CE mark approval for expanded indication covering large-bore venous closure.
PerQseal Elite is positioned as the first fully bioresorbable, sutureless solution in Europe for both arterial and venous access closure. The system features a unique inside-vessel deployment mechanism and requires no pre-procedure steps, offering advantages over conventional closure techniques that leave behind materials like collagen, metal implants, or sutures.